Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis.
Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis. Oncotarget. 2018 Jun 19;9(47):28445-28455 Authors: Maracle CX, Jeucken KCM, Helder B, van Gulik TM, Steins A, van Laarhoven HWM, Tas SW Abstract Angiogenesis is essential for colorectal cancer (CRC) progression, as demonstrated by the beneficial clinical effects of therapeutics inhibiting VEGF signaling. However, alternative mechanisms of neovascularization can develop, resulting in treatment failure. Previously we demonstrated NF-κB-inducing kinase (NIK) contributes to pathological angiogenesis. Here, we investigate NIK as a therapeutic target in endothelial cells (EC) in CRC. To determine NIK expression levels in CRC tissues, we immunostained both primary colorectal tumors and tumors metastasized to the liver. Additionally, a 3D tumor-stromal cell interaction model was developed including EC, fibroblasts and CRC cells to study tumor angiogenesis. This model tested efficacy of NIK-targeting siRNA (siNIK) in EC alone or in combination with the anti-VEGF antibody, bevacizumab. Both primary CRC and liver metastases contained blood vessels expressing NIK. In patients receiving chemotherapy plus bevacizumab, immature NIK+ vessels (p
Conclusion: Current review has been highlighted on the novel medicinal agents from plant sources have potential effects against many types of cancer, which have been supported by clinical trials. The main findings of these active novel medicinal agents were also summarized and discussed here.
CONCLUSIONS: Autophagy might play a role as a self-defense mechanism in hypoxia-treated colon cancer cells, and its inhibition could be a promising strategy for the adjuvant chemotherapy of colon cancer. PMID: 30779071 [PubMed - in process]
ConclusionsWe believe that in application to over 50 % of human cancers expressing uMUC1, our results could provide insight into overall assessment of therapeutic response based on its expression as defined by non-invasive MN-EPPT-enhanced MRI.
AbstractPurpose of ReviewPeritoneal metastases (PM) secondary to colorectal cancer is associated with a poor prognosis. However, cytoreductive surgery with hyperthermia intraperitoneal chemotherapy (CRS/HIPEC) has risen to a more accepted roll in the treatment of peritoneal metastatic disease for various cancers; colorectal cancer is no exception. This review aims to discuss the recent updates and findings for treatment of peritoneal disease secondary to colorectal cancer, especially with respect to individualized patient factors that affect outcomes.Recent FindingsThere are many new studies showing the validity of cytored...
ConclusionsWe found no consistent association between pre-chemotherapy PIM defined by STOPP and outcomes.
Publication date: 1 May 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 177Author(s): Menghang Zu, Lijun Ma, Xueqing Zhang, Dengchao Xie, Yuejun Kang, Bo XiaoAbstractTargeted delivery of chemotherapeutic drugs to tumors is a major challenge in colon cancer chemotherapy. To overcome this bottleneck, we loaded camptothecin (CPT) into polymeric nanoparticles (NPs), and further functionalized their surface with chondroitin sulfate (CS). The resulting CS-CPT-NPs had a desirable hydrodynamic diameter (289 nm), narrow particle size distribution (polydispersity index = 0.192) and neutral surface cha...
In this study, 20(S)-ginsenoside (Rg3) co-loaded poly(ethylene glycol)-block-poly(L-glutamic acid-co-L-phenylalanine) (mPEG-b-P(Glu-co-Phe)) nanoparticles (Rg3-NPs) were prepared. mPEG-b-P(Glu-co-Phe)-based drug delivery systems are pH sensitive that can target cancer cells and circulate for longer in blood. Rg3 could be released rapidly from the nanoparticles within tumor cells. A subcutaneous colon cancer mouse model was developed to evaluate the anticancer efficiency of the Rg3-NPs. The in vivo study indicated that the Rg3-NPs could significantly inhibit tumor proliferation by decreasing the expressions of proliferating...
Conditions: Metastatic Malignant Neoplasm in the Liver; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 Interventions: Procedure: Hepatectomy; Biological: Pembrolizumab; Drug: FOLFOX regimen Sponsors: University of California, San Francisco; National Cancer Institute (NCI) Not yet recruiting
ConclusionBiweekly SOX regimen with reintroduction of oxaliplatin could be exploitable as the third- and/or later-line treatments for patients with mCRC.
DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer, Published online: 18 February 2019; doi:10.1038/s41418-019-0303-zDUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer